Compare DECK & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DECK | WST |
|---|---|---|
| Founded | 1973 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2B | 25.6B |
| IPO Year | 1996 | 2004 |
| Metric | DECK | WST |
|---|---|---|
| Price | $93.84 | $351.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 23 | 7 |
| Target Price | $122.45 | ★ $325.86 |
| AVG Volume (30 Days) | ★ 2.1M | 654.8K |
| Earning Date | 05-21-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.30% |
| EPS Growth | ★ 10.90 | 1.49 |
| EPS | 0.94 | ★ 4.07 |
| Revenue | ★ $5,472,296,000.00 | $2,886,900,000.00 |
| Revenue This Year | $11.16 | $6.76 |
| Revenue Next Year | $6.96 | $6.22 |
| P/E Ratio | $103.59 | ★ $86.84 |
| Revenue Growth | ★ 9.76 | 1.95 |
| 52 Week Low | $78.91 | $223.83 |
| 52 Week High | $125.45 | $386.00 |
| Indicator | DECK | WST |
|---|---|---|
| Relative Strength Index (RSI) | 35.56 | 54.77 |
| Support Level | $92.22 | $349.41 |
| Resistance Level | $106.24 | $367.66 |
| Average True Range (ATR) | 3.42 | 10.54 |
| MACD | -0.45 | 0.30 |
| Stochastic Oscillator | 12.27 | 43.93 |
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2026, Ugg and Hoka accounted for 50% and 47% of total sales, respectively. The firm also markets a niche sandal brand Teva. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and has more than 200 company-operated stores, about half of which are outlets. The firm generated 58% of its fiscal 2026 sales in the United States.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.